OncoOne Raises €13M Series A to Develop First-in-Class Cancer Treatments

Austrian startup OncoOne has closed its first round of venture capital funding after raising €13M to investigate a new treatment target against solid tumor cancers.

Investment in the Series A funding included public grants from the Austrian Research Promotion Agency and the promotional bank of the Austrian federal government, the Austria Wirtschaftsservice Gesellschaft, along with contributions from two family offices.

OncoOne will use the financing to develop drugs targeting an oxidized version of an immune protein called macrophage migration inhibitory factor (oxMIF), which is only present in diseased tissue.  

ADVERTISEMENT

The startup will initially focus on the high-need areas of colorectal, pancreatic, lung and ovarian cancer, with the goal of rapidly entering clinical trials. As oxMIF is not indication-specific, the company has the potential to expand its pipeline to other cancers later down the line.

OncoOne sets itself apart from the otherwise crowded oncology space by being the only biotech to investigate the unrecognized target, oxMIF,” OncoOne CEO Randolf Kerschbaumer told me.

“Its apparent exclusive presence in afflicted tissue and high tumor specificity separate oxMIF from other targets typically used to battle cancer.” 

Unlike oxMIF’s non-oxidized form, MIF — which is present in both healthy and unhealthy tissue — oxMIF appears to be present only in diseased tissue rendering it a useful candidate for direct targeting in cancer treatments.

A 2016 study published by members of OncoOne’s team found that anti-oxMIF antibodies could make cancer cells in the lab more vulnerable to chemotherapy drugs such as cisplatin. In addition, a 2015 study from the same team suggested that blocking oxMIF could also treat inflammatory conditions such as psoriasis and inflammatory bowel disease.

According to Kerschbaumer, the company expects to develop first-in-class cancer drugs with this target, and then license them out to big pharma companies as a business model.  


Images from Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.